Literature DB >> 9210066

Advantage of treating anaplastic gliomas with aggressive protocol combining chemotherapy and radiotherapy.

A Boiardi1, A Silvani, A Pozzi, M Farinotti, L Fariselli, G Broggi, A Salmaggi.   

Abstract

We devised a treatment protocol for anaplastic gliomas consisting of:(a) chemotherapy prior to radiotherapy (b) a second chemotherapy regimen at tumor recurrence (c) repeated surgery whenever possible. 41 Anaplastic Astrocytoma (AA), 16 Anaplastic oligoastrocytoma (AOA) and 14 anaplastic oligodendroglioma (AOD) patients were treated. After surgery all patients received 5-6 cycles of carmustine+Cisplatinum chemotherapy. Radiotherapy was started during the last 2-3 cycles of chemotherapy. 17 patients (30.5%) were reoperated on at recurrence. All recurring patients underwent PVC chemotherapy. At this moment disease recurred in 56 patients. Median TTP was 24.5, 38.7 and 58.2 months for AA, AOA and AOD respectively. Median ST was 38.8, 71.8 and 73 months. In conclusion our sandwich protocol of prior chemotherapy, overlapping irradiation with second chemotherapy and, in favourable cases, a second surgical intervention, is of benefit in patients with anaplastic gliomas.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9210066     DOI: 10.1023/a:1005705624858

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  29 in total

1.  Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma.

Authors:  M J Winger; D R Macdonald; J G Cairncross
Journal:  J Neurosurg       Date:  1989-10       Impact factor: 5.115

2.  Eight drugs in one day chemotherapy for brain tumors: experience in 107 children and rationale for preradiation chemotherapy.

Authors:  T W Pendergrass; J M Milstein; J R Geyer; A F Mulne; E J Kosnik; J D Morris; R L Heideman; F B Ruymann; J T Stuntz; W A Bleyer
Journal:  J Clin Oncol       Date:  1987-08       Impact factor: 44.544

3.  Oligodendroglioma: an analysis of 42 cases.

Authors:  I M Wilkinson; J R Anderson; A E Holmes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-03       Impact factor: 10.154

4.  Malignant glioma. Results of combined modality therapy.

Authors:  J S Cooper; T L Borok; J Ransohoff; R J Carella
Journal:  JAMA       Date:  1982-07-02       Impact factor: 56.272

5.  Preradiation chemotherapy for newly diagnosed childhood brain tumors. A modified Phase II trial.

Authors:  J C Allen; L Helson; B Jereb
Journal:  Cancer       Date:  1983-12-01       Impact factor: 6.860

6.  Oligodendroglioma. Histologic evaluation and prognosis.

Authors:  S J Mørk; T B Halvorsen; K F Lindegaard; G E Eide
Journal:  J Neuropathol Exp Neurol       Date:  1986-01       Impact factor: 3.685

7.  Oligodendroglioma. An analysis of the value of radiation therapy.

Authors:  D E Bullard; C E Rawlings; B Phillips; E B Cox; S C Schold; P Burger; E C Halperin
Journal:  Cancer       Date:  1987-11-01       Impact factor: 6.860

8.  Evaluation of CCNU, VM-26 plus CCNU, and procarbazine in supratentorial brain gliomas. Final evaluation of a randomized study. European Organization for Research on Treatment of Cancer (EORTC) Brain Tumor Group.

Authors: 
Journal:  J Neurosurg       Date:  1981-07       Impact factor: 5.115

9.  Survival and prognosis of patients with astrocytoma with atypical or anaplastic features.

Authors:  D F Nelson; J S Nelson; D R Davis; C H Chang; T W Griffin; T F Pajak
Journal:  J Neurooncol       Date:  1985       Impact factor: 4.130

Review 10.  Imaging of adult central nervous system primary malignant gliomas. Staging and follow-up.

Authors:  R A Zimmerman
Journal:  Cancer       Date:  1991-02-15       Impact factor: 6.860

View more
  6 in total

1.  The conditional survival statistics for survivors with primary supratentorial astrocytic tumors.

Authors:  S L Hwang; Y H Yang; A S Lieu; M C Chuang; S J Chang; Y Y Chang; H J Lin; S L Howng
Journal:  J Neurooncol       Date:  2000-12       Impact factor: 4.130

2.  Accelerated radiotherapy with concomitant ACNU/Ara-C for the treatment of malignant glioma.

Authors:  K Anders; G G Grabenbauer; U Schuchardt; R Fahlbusch; R Fietkau; R Sauer; P Krauseneck
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

3.  Cisplatin and BCNU chemotherapy for anaplastic oligoastrocytomas.

Authors:  A Boiardi; M Eoli; A Salmaggi; B Pollo; I Milanesi; G Broggi; A Silvani
Journal:  J Neurooncol       Date:  2000-08       Impact factor: 4.130

4.  Safety and efficacy of a novel cannabinoid chemotherapeutic, KM-233, for the treatment of high-grade glioma.

Authors:  Christopher Duntsch; Murali Krishna Divi; Terreia Jones; Qihong Zhou; Mathangi Krishnamurthy; Peter Boehm; George Wood; Allen Sills; Bob M Moore
Journal:  J Neurooncol       Date:  2005-11-29       Impact factor: 4.130

5.  Longitudinal microPET imaging of brain tumor growth with F-18-labeled RGD peptide.

Authors:  Xiaoyuan Chen; Ryan Park; Vazgen Khankaldyyan; Ignacio Gonzales-Gomez; Michel Tohme; Rex A Moats; James R Bading; Walter E Laug; Peter S Conti
Journal:  Mol Imaging Biol       Date:  2006 Jan-Feb       Impact factor: 3.488

Review 6.  Oligodendroglioma.

Authors:  Thomas L Ellis; Volker W Stieber; Rebekah C Austin
Journal:  Curr Treat Options Oncol       Date:  2003-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.